Lumida
/HCAT
⌘K
Health Catalyst Inc

Health Catalyst Inc

HCAT
$1.70USD-1.73%-0.03 today

MARKET CAP

127.9M

P/E (TTM)

8.6x

FWD P/E

DAY RANGE

$2 – $2

52W RANGE

$1
$4

AI Summary

Stalk
StalkMedium

HCAT is in a Stage 2 advance with clear higher highs and higher lows and rising short-term EMAs, but price is extended above EMAs and overbought in the short term. Medium-term bias remains bullish after the recent breakout, yet execution should wait for a pullback into the rising 9/20 EMA zone or the lower portion of the breakout range before participation.

  • Q2 revenue $70.5M topped guidance; adjusted gross margin rose to 51% YoY
  • VitalWare divestiture cut $160M debt and $19M in annual interest expense
  • Consensus FY26 EPS cut to –$2.41 and revenue down to $247.4M from $268.2M
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$241.9M$276.2M$295.9M$306.6M$311.1M
YoY %+28.1%+14.2%+7.1%+3.6%+1.5%
P / Sales7.8x2.0x1.7x1.4x0.5x
EV / Sales8.3x2.8x2.5x2.2x1.2x
Gross Profit, Adj.$117.6M$133.2M$131.8M$140.8M$151.7M
YoY %+29.5%+13.3%-1.0%+6.8%+7.7%
Margin %48.6%48.2%44.5%45.9%48.7%
EV / Gross Profit17.0x5.8x5.6x4.8x2.5x
EBITDA, Adj.$-106.1M$-91.7M$-84.7M$-28.4M$-131,000
YoY %-37.1%+13.6%+7.7%+66.5%+99.5%
Margin %-43.9%-33.2%-28.6%-9.3%-0.0%
EV / EBITDA-18.8x-8.4x-8.8x-23.6x-2848.1x
EBIT$-143.7M$-140.0M$-126.9M$-69.8M$-160.9M
YoY %-49.4%+2.5%+9.4%+45.0%-130.4%
Margin %-59.4%-50.7%-42.9%-22.8%-51.7%
EV / EBIT-13.9x-5.5x-5.9x-9.6x-2.3x
Net Income$-153.2M$-137.4M$-118.1M$-69.5M$-178.0M
YoY %-33.2%+10.3%+14.0%+41.2%-156.1%
Net Margin-63.3%-49.7%-39.9%-22.7%-57.2%
EPS (GAAP)-$3.23-$2.63-$2.09-$1.15-$2.55
YoY %-11.0%+18.6%+20.5%+45.0%-121.7%